Nishikawa Y, Shindo T, Ishii K, Nakamura H, Kon T, Uno H
Chem Pharm Bull (Tokyo). 1989 Jan;37(1):100-5. doi: 10.1248/cpb.37.100.
A new series of acrylamide derivatives (7-10) were synthesized. Antiallergic activity of these compounds was evaluated and their structure-activity relationships were examined. Compound 10d, N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-3-(3-pyridyl)acrylamid e, showed antiallergic activity equivalent or superior to that of ketotifen in the rat passive cutaneous anaphylaxis (PCA) test by oral administration. Compound 10d, unlike ketotifen, had more potent in vitro 5-lipoxygenase inhibitory activity than caffeic acid, whereas its in vitro antihistamine activity was weaker than that of ketotifen. In addition, its inhibitory activity against histamine release from rat mast cells was approximately two-thirds as potent as that of disodium cromoglycate (DSCG). Compound 10d is a promising agent for treating a variety of allergic diseases.
合成了一系列新的丙烯酰胺衍生物(7 - 10)。评估了这些化合物的抗过敏活性,并研究了它们的构效关系。化合物10d,N - [4 - (4 - 二苯甲基 - 1 - 哌嗪基)丁基] - 3 - (3 - 吡啶基)丙烯酰胺,在大鼠被动皮肤过敏反应(PCA)试验中通过口服给药显示出与酮替芬相当或更强的抗过敏活性。与酮替芬不同,化合物10d在体外具有比咖啡酸更强的5 - 脂氧合酶抑制活性,而其体外抗组胺活性比酮替芬弱。此外,其对大鼠肥大细胞组胺释放的抑制活性约为色甘酸钠(DSCG)的三分之二。化合物10d是治疗多种过敏性疾病的有前景的药物。